Sodium Polystyrene Sulfonate (Kayexalate) for Hyperkalemia: Evidence‑Based Recommendations

Efficacy of Oral Dosing

A 30 g oral dose reduces serum potassium by an average of 1.25 mEq/L over 7 days in patients with chronic kidney disease. This finding derives from a randomized, double‑blind, placebo‑controlled trial (Level A evidence). 1
In the same trial, a single 30 g daily dose produced a mean potassium reduction of ‑1.04 mEq/L (95 % CI ‑1.37 to ‑0.71; P < 0.001) compared with placebo in adults with mild hyperkalemia (5.0–5.9 mEq/L) and CKD. (Level A). 1
Rectal administration (30–50 g every 6 h) yields only a modest potassium decrease of ≈0.22 mEq/L, and all patients remained hyperkalemic in observational cohorts. (Level B). 1

Sodium polystyrene sulfonate has a delayed and variable onset (several hours to days); post‑dose potassium levels typically fall 14–16 h after administration, making it unsuitable for emergency treatment of life‑threatening hyperkalemia. (Level B). 1
To avoid drug‑drug interactions, the resin should be taken at least 3 h before or after other oral medications; a 6‑h separation is recommended in patients with gastroparesis because the resin non‑selectively binds concomitant drugs. (Level B). 1

Overall mortality associated with sodium polystyrene sulfonate therapy is reported at 33 %. Fatal intestinal necrosis, colonic necrosis, ischemic colitis, and gastrointestinal perforation have been documented, most often when the resin is combined with sorbitol. (Level B). 1
Concomitant sorbitol use markedly increases the risk of severe gastrointestinal injury and is therefore not recommended. (Level B). 1
Each 15 g dose contains approximately 1500 mg of sodium, which can exacerbate fluid overload in patients prone to volume retention. (Level B). 1

Sodium polystyrene sulfonate non‑selectively binds calcium and magnesium as well as potassium, leading to potential hypocalcemia, hypomagnesemia, and severe hypokalemia; therefore serum potassium, calcium, and magnesium should be monitored during therapy. (Level B). 1

The totality of evidence for chronic SPS use rests on a single small 7‑day randomized trial (N = 33). Short‑term efficacy is inconsistent, with modest potassium reductions of 0.14–0.58 mEq/L over control, raising questions about clinical significance relative to cost and adverse‑event risk. (Level C). 1

Newer agents—sodium zirconium cyclosilicate (SZC) and patiromer—demonstrate superior safety, with no reported fatal gastrointestinal injuries, and provide a faster, more predictable onset of action (SZC onset ≈1 h versus several hours for SPS). (Level B). 1